<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="85562">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01758250</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00039256</org_study_id>
    <nct_id>NCT01758250</nct_id>
  </id_info>
  <brief_title>Microvascular and Fibrosis Imaging Study</brief_title>
  <official_title>Mechanistic Study: Non-Invasive Cutaneous Microvascular and Fibrosis Imaging of Patients With Systemic Sclerosis, Sickle Cell Disease and Chronic Graft-Versus-Host Disease (GVHD) Compared to Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, Laser Doppler Flowmetry (LDF), Laser Doppler Imaging (LDI), Orthogonal
      Polarization Spectral Imaging (OPSI), Nail fold video capillaroscopy (NVC) and Optical
      Coherence Tomography (OCT) will be used to assess differences in microvascular function and
      density of oral mucosa and skin in subjects with 1) autoimmune diseases with cutaneous
      involvement: systemic sclerosis (SSc), morphea, dermatomyositis, cutaneous lupus and
      vasculitis, 2) sickle cell disease (SCD) and 3) chronic graft-versus-host disease (GVHD)
      compared to healthy subjects.  The microvascular changes will be compared to overall
      treatment response in patients with scleroderma and chronic GVHD as assessments will be made
      before and after the patients start treatment for their diseases and determine if these
      imaging techniques provide valuable and reproducible data when assessing a patient's
      response to treatment for those diseases.  In addition, the application of Acoustic
      Radiation Force Impulse (ARFI) in determining cutaneous thickness in patients with SSc, GVHD
      and morphea will be evaluated.

      The investigators hypothesize that the vascular and dermal structures are altered in
      patients with autoimmune disease, SCD and chronic GVHD. In addition, they hypothesize that
      imaging modalities such as LDF, LDI, OCT, NVC, OPSI and ARFI can quantify such structural
      alterations and can be used to 1) detect early disease activity, 2) quantify and assess
      response to therapy and 3) quantify and correlate with overall disease activity.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">January 2017</completion_date>
  <primary_completion_date type="Anticipated">January 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case Control, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Microvascular density in oral mucosa and skin</measure>
    <time_frame>over 24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Microvascular density as evaluated using LDF, LDI, OPSI, OCT, NVC and AFRI, will be compared between subjects with and without disease.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Microvascular Perfusion in oral mucosa and skin</measure>
    <time_frame>over 24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Microvascular perfusion as evaluated using LDF, LDI, OPSI, OCT, NVC, and AFRI, will be compared between subjects with and without disease.</description>
  </primary_outcome>
  <number_of_groups>6</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Autoimmune Diseases</condition>
  <condition>Sickle Cell Disease</condition>
  <condition>Chronic Graft Versus Host Disease</condition>
  <arm_group>
    <arm_group_label>Systemic Sclerosis</arm_group_label>
    <description>Patients with SSc will have imaging studies performed at baseline and at 3, 6, 9, 12, 15, 18, 21 and 24 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GVHD</arm_group_label>
    <description>Patients with GVHD will have imaging studies performed at baseline and at 3, 6, 9, 12, 18 and 24 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Undergoing HSCT</arm_group_label>
    <description>Patients who are about to undergo HSCT will have imaging studies performed at 1 week pre-transplantation, day 40 and 80 post transplantation and at 3 months, 6 months, 12 months 18 months and 24 months post-transplant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <description>Healthy Controls and Controls with hematologic and solid organ malignancies and dermatitis will have imaging studies performed at a single point in time.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sickle cell disease</arm_group_label>
    <description>Patients with SCD will have imaging studies performed at baseline and at 3, 6, 9, 12, 15, 18, 21 and 24 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cutaneous fibrosing disorder</arm_group_label>
    <description>Patients with active cutaneous fibrosing disorder will have imaging studies performed at a single point in time.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Acoustic Radiation Force Impulse (ARFI)</intervention_name>
    <arm_group_label>Systemic Sclerosis</arm_group_label>
    <arm_group_label>GVHD</arm_group_label>
    <arm_group_label>Undergoing HSCT</arm_group_label>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_label>Sickle cell disease</arm_group_label>
    <arm_group_label>Cutaneous fibrosing disorder</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laser Doppler Flowmetry (LDF)</intervention_name>
    <arm_group_label>Systemic Sclerosis</arm_group_label>
    <arm_group_label>GVHD</arm_group_label>
    <arm_group_label>Undergoing HSCT</arm_group_label>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_label>Sickle cell disease</arm_group_label>
    <arm_group_label>Cutaneous fibrosing disorder</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laser Doppler Perfusion Imaging (LDI)</intervention_name>
    <arm_group_label>Systemic Sclerosis</arm_group_label>
    <arm_group_label>GVHD</arm_group_label>
    <arm_group_label>Undergoing HSCT</arm_group_label>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_label>Sickle cell disease</arm_group_label>
    <arm_group_label>Cutaneous fibrosing disorder</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Optical Coherence Tomography  (OCT)</intervention_name>
    <arm_group_label>Systemic Sclerosis</arm_group_label>
    <arm_group_label>GVHD</arm_group_label>
    <arm_group_label>Undergoing HSCT</arm_group_label>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_label>Sickle cell disease</arm_group_label>
    <arm_group_label>Cutaneous fibrosing disorder</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Orthogonal Polarization Spectral Imaging  (OPSI)</intervention_name>
    <arm_group_label>Systemic Sclerosis</arm_group_label>
    <arm_group_label>GVHD</arm_group_label>
    <arm_group_label>Undergoing HSCT</arm_group_label>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_label>Sickle cell disease</arm_group_label>
    <arm_group_label>Cutaneous fibrosing disorder</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Nail fold video capillaroscopy (NVC)</intervention_name>
    <arm_group_label>Systemic Sclerosis</arm_group_label>
    <arm_group_label>GVHD</arm_group_label>
    <arm_group_label>Undergoing HSCT</arm_group_label>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_label>Sickle cell disease</arm_group_label>
    <arm_group_label>Cutaneous fibrosing disorder</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patient population at Duke University Medical Center and healthy controls
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects above the age of 18 who are capable of giving informed consent with one of
             the following conditions: Scleroderma, Graft vs Host Disease, Sickle Cell Disease,
             Morphea, Connective Tissue Disease with cutaneous manifestations: cutaneous lupus,
             dermatomyositis, vasculitis, patients who are undergoing HSCT, or patients with a
             diagnosis of hematologic and non-hematologic malignancies without GVHD

          -  Control patients include normal healthy controls above the age of 18 who are capable
             of giving informed consent.

        Exclusion Criteria:

          -  Patients who experience discomfort, will be prone to experience discomfort or cannot
             tolerate the position required for the imaging studies.

          -  Subjects unable to provide informed consent.

          -  Smokers, patients unable to tolerate caffeine avoidance for the day of the study.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Keith Sullivan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Adela Cardones, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Krista Rowe, RN</last_name>
    <phone>919-684-7115</phone>
    <email>krista.rowe@duke.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 10, 2013</lastchanged_date>
  <firstreceived_date>December 26, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Autoimmune diseases with cutaneous involvement</keyword>
  <keyword>Systemic sclerosis</keyword>
  <keyword>Scleroderma</keyword>
  <keyword>Morphea</keyword>
  <keyword>Dermatomyositis</keyword>
  <keyword>Cutaneous lupus</keyword>
  <keyword>Vasculitis</keyword>
  <keyword>Sickle Cell Disease</keyword>
  <keyword>Graft versus Host Disease</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
    <mesh_term>Autoimmune Diseases</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Graft vs Host Disease</mesh_term>
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Scleroderma, Diffuse</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
